Wednesday, April 22, 2015

Kyle Bass files IPR against patent related to Imbruvica (Ibrutinib)

FiercePharma reports on another IPR filed by hedge funder Kyle Bass against a drug patent.  This one relates to the '090 patent on Imbruvica:

After Bass' petition was filed Monday, Pharmacyclics shares dropped. Not by a huge amount, as Acorda's did after the Ampyra challenge. But plenty to deliver a significantly bigger profit--provided you were short enough.


Ibrutinib was first designed and synthesized at Celera Genomics .  
Approved by the FDA for treatment of mantle cell lymphoma, it is being studied for use against other afflictions, including diffuse large B-cell lymphoma and multiple myeloma.


Post a Comment

<< Home